Focus: Immunovant is a public-stage biotechnology company focused on monoclonal antibody therapeutics for autoimmune diseases spanning neurology, immunology, and endocrinology. The company operates from Durham, NC with a lean headcount and is advancing a diversified pipeline of Phase 2 and Phase 3 programs.
Profile data last refreshed 14h ago · AI intelligence enriched 1w ago
Growing — net +5 jobs in 30d
9 jobs added vs 4 removed. Steady team buildout.
Immunovant offers meaningful pipeline exposure and scientific depth in autoimmune biology, but suits early-career or specialist roles accepting pre-revenue risk and limited hiring velocity.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Immunovant
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Immunovant's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Ramaswamy-linked drug crashes wiped millions from public pension investments, including Ohio teachers’ fund - TiffinOhio.net
Ramaswamy-linked drug crashes wiped millions from public pension investments, including Ohio teachers’ fund TiffinOhio.net
HanAll Biopharma halts lupus bid, pivots to arthritis as China setback deepens - Chosunbiz
HanAll Biopharma halts lupus bid, pivots to arthritis as China setback deepens Chosunbiz
HanAll Biopharma Halts Lupus Drug Trial, Pivots to Rheumatoid Arthritis - finance.biggo.com
HanAll Biopharma Halts Lupus Drug Trial, Pivots to Rheumatoid Arthritis finance.biggo.com
Immunovant shares drop 6% after lupus drug stud... - Pluang
Immunovant shares drop 6% after lupus drug stud... Pluang
Immunovant drops IMVT-1402 in cutaneous lupus after proof-of-concept miss - AllSci
Immunovant drops IMVT-1402 in cutaneous lupus after proof-of-concept miss AllSci
Immunovant halts lupus skin drug after trial misses significance; Korea partner pivots - Chosunbiz
Immunovant halts lupus skin drug after trial misses significance; Korea partner pivots Chosunbiz
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Lupus Nexus: developing a prospective registry, biorepository and data exchange platform to foster global collaborations, accelerate research innovation and advance precision medicine in lupus.
Burden of Disease in Myasthenia Gravis: A Targeted Literature Review.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo